Latest news with #Nature'sSunshine
Yahoo
27-06-2025
- Business
- Yahoo
5 Revealing Analyst Questions From Nature's Sunshine's Q1 Earnings Call
Nature's Sunshine's first quarter was marked by strong international performance and effective risk management amid a complex trading environment. The company's results exceeded Wall Street's expectations, with CEO Terrence Moorehead attributing the outperformance to robust demand in Asia Pacific and Europe. Moorehead highlighted, 'Our strategy to refocus the business on high-velocity products that offer an attractive repay purchase opportunity continued to drive strong order growth, while the expansion of our Subscribe & Thrive autoship program helped improve customer activation and drive orders.' The company also increased inventory levels to hedge against evolving tariffs and supply disruptions, supporting continued product availability. Is now the time to buy NATR? Find out in our full research report (it's free). Revenue: $113.2 million vs analyst estimates of $109.3 million (2% year-on-year growth, 3.6% beat) Adjusted EPS: $0.25 vs analyst estimates of $0.17 (51.5% beat) Adjusted EBITDA: $10.97 million vs analyst estimates of $9.75 million (9.7% margin, 12.5% beat) The company reconfirmed its revenue guidance for the full year of $457.5 million at the midpoint EBITDA guidance for the full year is $41 million at the midpoint, below analyst estimates of $42.98 million Operating Margin: 5.4%, up from 4.2% in the same quarter last year Market Capitalization: $263.5 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Brian Holland (Davidson) asked whether revenue guidance reflected an expectation for worsening macroeconomic trends or a continuation of Q1 conditions. CFO Shane Jones said guidance was conservative, designed to encompass both ongoing instability and potential recession scenarios. Brian Holland (Davidson) requested clarification on tariff assumptions embedded in guidance. Jones replied that the company had been 'very conservative, very thoughtful' in preparing for a range of tariff impacts, emphasizing ongoing flexibility. Brian Holland (Davidson) inquired about the timing and disruption risk of the new digital toolkit for practitioners. CEO Terrence Moorehead stated the launch remains on track for the second half and will not disrupt current processes, aiming instead to provide incremental benefits. Susan Anderson (Canaccord Genuity) asked about drivers of continued growth in Europe and Asia. Moorehead pointed to strong sales and marketing fundamentals and noted ongoing opportunities, especially in Japan, but cautioned about challenging comparisons later in the year. Susan Anderson (Canaccord Genuity) sought details on strategies to improve North American practitioner and retail channels. Moorehead highlighted new leadership, tools, and marketing initiatives as central to rebuilding fundamentals and supporting growth. In the quarters ahead, the StockStory team will monitor (1) the adoption and effectiveness of the new practitioner digital toolkit in North America, (2) the company's ability to sustain customer and order growth in key Asia Pacific and European markets despite tougher year-over-year comparisons, and (3) the impact of ongoing tariff and macroeconomic pressures on gross margin and supply chain stability. Execution on digital and field initiatives will be critical to maintaining overall growth momentum. Nature's Sunshine currently trades at $14.53, up from $12.46 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
27-06-2025
- Business
- Yahoo
Why Nature's Sunshine (NATR) Shares Are Getting Obliterated Today
Shares of wellness products company Nature's Sunshine (NASDAQ:NATR) fell 8.5% in the afternoon session after the company announced the pricing of a secondary stock offering by a major shareholder. The offering involves major shareholder Fosun Pharma USA selling up to 2.85 million shares at a price of $12.00 per share. The stock is trading down to align with the offering price, which represents a significant discount to its previous closing price. While the company itself is not selling any new shares and will not receive any proceeds, the large block of stock hitting the market is creating selling pressure. Nature's Sunshine did note that it may buy back up to $15 million worth of shares from the offering as part of its existing repurchase program, which could help absorb some of the supply. The shares closed the day at $14.30, down 3.1% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Nature's Sunshine? Access our full analysis report here, it's free. Nature's Sunshine's shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 24 days ago when the stock dropped 7.2% on the news that CEO Terrence Moorehead, announced his decision to step down from his role. The board also announced the search for his successor, and Moorehead will remain in his role until a new CEO is appointed. This interim period introduced leadership uncertainty, something the market generally dislikes. Nature's Sunshine is down 4.3% since the beginning of the year, and at $13.94 per share, it is trading 20% below its 52-week high of $17.43 from November 2024. Investors who bought $1,000 worth of Nature's Sunshine's shares 5 years ago would now be looking at an investment worth $1,758. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
26-06-2025
- Business
- Associated Press
Nature's Sunshine Products, Inc. Announces Pricing of Secondary Public Offering of Common Stock
LEHI, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ: NATR) ('Nature's Sunshine' or the 'Company'), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the pricing of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the 'Selling Stockholder'). The shares of common stock are being sold at a price of $12.00 per share. The offering is expected to close on June 27, 2025, subject to customary closing conditions. The Selling Stockholder will receive all of the net proceeds from the offering. Nature's Sunshine is not selling any shares of common stock in the offering and will not receive any proceeds from the offering. The Selling Stockholder will pay any underwriting discounts and commissions and transfer taxes attributable to the resale of the shares of the Company's common stock the Selling Stockholder holds, as well as certain reasonable out-of-pocket expenses incurred by the underwriters. The Company will bear all other costs, fees and expenses incurred in effecting the registration of the shares in the offering. As part of the offering, the Company has agreed with the Selling Stockholder that it may purchase up to $15.0 million of the shares of its common stock that are subject to the offering from the underwriters at the public offering price as part of the Company's previously announced share repurchase program. However, the Company has not agreed to purchase a minimum amount of shares and may determine to purchase fewer or no shares in this offering. Accordingly, there can be no guarantee that the Company will purchase any shares in this offering and investors should not rely on such agreement as evidence that this offering is more likely to be successful. The Company anticipates that the stock repurchase, if any, would be funded from cash on-hand and funds drawn from its credit facility. D.A. Davidson & Co. is acting as sole book‐running manager and representative of the underwriters for the offering. The common stock is being offered pursuant to a shelf registration statement (which includes a base prospectus) on Form S-3 (File No. 333-287882) that was filed by the Company with the Securities and Exchange Commission (the 'SEC') on June 9, 2025 and became effective on June 18, 2025. A preliminary prospectus supplement relating to these securities has been filed with the SEC. Before you invest, you should read the registration statement, the base prospectus, the preliminary prospectus supplement, and other documents filed with the SEC and incorporated by reference therein for more complete information about Nature's Sunshine and this offering. You may obtain these documents free of charge by visiting EDGAR on the SEC's website at The offering is being made only by means of a prospectus and related prospectus supplement, copies of which, when available, may be obtained on the SEC's website, or from D.A. Davidson & Co., Attention: Syndicate Department, 8 Third Street North, Great Falls, MT 59401, by telephone at (800) 332-5915 and by e-mail: [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Nature's Sunshine Products Nature's Sunshine Products (NASDAQ: NATR), a leading natural health and wellness company, markets and distributes nutritional and personal care products in more than 40 countries. Nature's Sunshine manufactures most of its products through its own state-of-the-art facilities to ensure its products continue to set the standard for the highest quality, safety and efficacy on the market today. Additional information about the company can be obtained at its website, Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including statements related to the anticipated closing of the offering and the concurrent share repurchase. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as 'believe,' 'hope,' 'may,' 'anticipate,' 'should,' 'intend,' 'plan,' 'will,' 'expect,' 'estimate,' 'project,' 'positioned,' 'strategy' and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, include, but are not limited to the completion of the offering and the concurrent share repurchase, the satisfaction of customary closing conditions related to the offering, the transition of leadership of the Company having a negative effect on the Company's future business expectations, and the risks associated with searching for a successor President and Chief Executive Officer taking longer than intended or not meeting the Board's expectations. These and other risks and uncertainties that could cause actual results to differ from predicted results are more fully detailed under the caption 'Risk Factors' in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this press release. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this press release. Investor Relations: Gateway Group, Inc. Cody Slach 1-949-574-3860 [email protected]
Business Insider
10-06-2025
- Business
- Business Insider
Nature's Sunshine files to sell 2.85M shares of common stock for holders
16:35 EDT Nature's Sunshine (NATR) files to sell 2.85M shares of common stock for holders Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
05-06-2025
- Business
- Yahoo
1 Safe-and-Steady Stock with Exciting Potential and 2 to Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. Finding the right balance between safety and returns isn't easy, which is why StockStory is here to help. That said, here is one low-volatility stock that could offer consistent gains and two stuck in limbo. Rolling One-Year Beta: 0.77 Started on a kitchen table in Utah, Nature's Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products. Why Are We Cautious About NATR? Flat sales over the last three years suggest it must innovate and find new ways to grow Modest revenue base of $456.6 million gives it less fixed cost leverage and fewer distribution channels than larger companies Earnings per share fell by 20.6% annually over the last three years while its revenue was flat, showing each sale was less profitable Nature's Sunshine's stock price of $14.13 implies a valuation ratio of 18.5x forward P/E. Dive into our free research report to see why there are better opportunities than NATR. Rolling One-Year Beta: 0.45 The first homebuilder to be listed on the NYSE, KB Home (NYSE:KB) is a homebuilding company targeting the first-time home buyer and move-up buyer markets. Why Do We Avoid KBH? Backlog has dropped by 22.9% on average over the past two years, suggesting it's losing orders as competition picks up Earnings per share have dipped by 5.3% annually over the past two years, which is concerning because stock prices follow EPS over the long term Free cash flow margin dropped by 5.5 percentage points over the last five years, implying the company became more capital intensive as competition picked up At $52.29 per share, KB Home trades at 6.6x forward P/E. Read our free research report to see why you should think twice about including KBH in your portfolio, it's free. Rolling One-Year Beta: 0.32 With over 100 million people served across its various businesses and a workforce of more than 400,000, UnitedHealth Group (NYSE:UNH) operates a health insurance business and Optum, a healthcare services division that provides everything from pharmacy benefits to primary care. Why Is UNH a Top Pick? Massive revenue base of $410.1 billion gives it meaningful leverage when negotiating reimbursement rates Share buybacks catapulted its annual earnings per share growth to 13.1%, which outperformed its revenue gains over the last five years ROIC punches in at 21.6%, illustrating management's expertise in identifying profitable investments UnitedHealth is trading at $300.85 per share, or 9.7x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
